Korro promoting Chappell to COO, adding Pearson to board
Plus: 3T hires Irving and updates from Q32 Bio, Garuda and Fibrocor
Korro Bio Inc. promoted Todd Chappell to COO from SVP, strategy and portfolio planning as the company prepares for a reverse merger with Frequency Therapeutics Inc. (NASDAQ:FREQ). Korro also appointed Tim Pearson, CEO of Carrick Therapeutics Ltd., chairman of GlycoMimetics Inc. (NASDAQ:GLYC) and former CFO of Tesaro Inc., to the company’s board, contingent on the reverse merger taking place. Korro is creating a CRISPR-independent version of RNA base editing that pairs antisense technology with an endogenous RNA-modifying enzyme to precisely swap single target bases. Frequency’s board is scheduled to vote on the reverse merger on Nov. 3.
3T Biosciences Inc. hired Bryan Irving as CSO and Estelle Marrer-Berger as chief development officer. Irving was a senior adviser at Frazier Life Sciences and CSO at Amunix Pharmaceuticals Inc.; Marrer-Berger was toxicology project leader at Roche (SIX:ROG; OTCQX:RHHBY). 3T is improving the tumor selectivity of TCR-based therapies...